Two labs process the same leukopak format from the same supplier and report yields that differ by a wide margin. Neither did anything wrong in the sense of breaking protocol. The variance comes from a handful of decisions that protocols tend to describe loosely, plus a couple of properties of the starting material that nobody controls once the bag has been filled.
Start from what the unit actually contains
A leukopak is specified by total nucleated cells, not by PBMC content, and those are different quantities. Total nucleated cells include granulocytes, which are not mononuclear and which density gradient separation is designed to remove. The mononuclear fraction is a proportion of the total, and that proportion varies by donor and by collection.
OrganaBio documents a minimum of 10 billion cells per single-donor whole leukopak unit, with whole, half, quarter and custom formats. Planning a PBMC yield from that figure means applying an expected mononuclear proportion and then a recovery factor for the isolation itself, and being explicit that both are estimates rather than specifications.
What reduces the number
| Factor | Effect on yield | Controllable? |
|---|---|---|
| Granulocyte content of the starting unit | Reduces mononuclear fraction and can disrupt the interface | Partly, through collection quality and time to processing |
| Time between collection and processing | Granulocyte carryover rises, cell state drifts | Supplier-side, structural |
| Dilution before layering | Under-dilution degrades separation | Yes |
| Layering technique | Disturbed interface mixes fractions | Yes |
| Centrifuge brake | Braking remixes a resolved gradient | Yes, and it is the most common single error |
| Temperature during separation | Density shifts with temperature | Yes |
| Number of wash steps | Each wash removes platelets and also cells | Yes |
The centrifuge brake deserves its own sentence. A gradient that has resolved cleanly can be remixed in the last few seconds of a spin by deceleration, and the resulting yield loss is often blamed on the material.
Granulocytes, the recurring theme
Granulocytes are the main contaminant in a PBMC preparation and the main reason yields disappoint. They are denser than mononuclear cells and should pellet below the gradient interface, which works well when the cells are fresh. As time passes granulocytes begin to change density, and a proportion of them start to band with the mononuclear layer instead of below it.
The practical consequence is that delay does not simply reduce PBMC yield, it also degrades PBMC purity, and it does both progressively. This is why the interval between collection and first processing is a supplier-side variable that lands on your bench. It is covered in more depth in the piece on granulocyte contamination.
Yield is not the only number that matters
A high yield of poorly recovered cells is not a good outcome. Yield, viability and purity move partly independently, and optimising for one at the expense of the others is a common and quiet mistake. Aggressive washing improves platelet removal and purity while costing yield. A gentler protocol preserves yield and carries more contamination forward.
The right balance depends on the downstream application, which means the protocol should be set by the assay rather than inherited. A preparation destined for a functional assay tolerates different compromises from one going into a phenotyping panel.
Or start from isolated material
Isolating PBMCs in house makes sense when the process is part of what is being studied, when unusual formats are needed, or when a downstream step is sensitive to how the isolation was done. It makes considerably less sense when the isolation is simply an obstacle between purchase and experiment, in which case the variance introduced is a cost with no return.
OrganaBio documents cryopreserved PBMCs isolated from the same donor program as the leukopaks, alongside isolated pan T cells and NK cells for programs that would otherwise perform a second isolation step themselves. Choosing between fresh and cryopreserved formats is covered in the fresh versus cryopreserved guide.
Frequently asked questions
How many PBMCs can I expect from a leukopak?
A leukopak is specified by total nucleated cells rather than PBMC content, and those are different quantities because total nucleated cells include granulocytes. Estimating PBMC yield means applying an expected mononuclear proportion and then a recovery factor for the isolation, both of which are estimates rather than specifications.
Why do two labs get different PBMC yields from the same leukopak format?
Dilution before layering, layering technique, whether the centrifuge brake was used, separation temperature and the number of wash steps all move the result, and protocols describe several of these loosely. Donor variation and time to processing account for the rest.
What is the most common technical error that costs yield?
Using the centrifuge brake. A gradient that has resolved cleanly can be remixed during deceleration, and the resulting loss is frequently attributed to the material rather than the spin.
Why does granulocyte contamination increase with time?
Granulocytes are denser than mononuclear cells and normally pellet below the gradient interface. As time from collection passes their density changes and a proportion begin to band with the mononuclear layer instead, so delay reduces both yield and purity progressively.
Should I optimise my protocol for yield?
Not in isolation. Yield, viability and purity move partly independently, and aggressive washing improves purity while costing yield. The right balance depends on the downstream application, so the protocol should be set by the assay rather than inherited.
Is it better to isolate PBMCs in house or buy them isolated?
In-house isolation makes sense when the process is part of what is being studied, when unusual formats are needed, or when a downstream step is sensitive to isolation method. When isolation is simply an obstacle between purchase and experiment, it adds variance without return.
Does the leukopak format affect PBMC yield per cell?
Formats differ in absolute content rather than in the proportion recovered, so the yield calculation scales. Whole, half, quarter and custom formats are documented, and the practical difference is how much material you are committing to a single processing run.
Talk to OrganaBio
Need this material for a specific process?
Formats, vial sizes and donor characterization vary by product, and custom formats are documented where a process needs them. Tell us what your process requires and the scientific team will confirm what can be supplied.
